PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Nature

Volumn 545, Issue 7655, 2017, Pages 495-499

  Gordon, Sydney R ^a,b   Maute, Roy L ^a,b   Dulken, Ben W ^a,c   Hutter, Gregor ^a,d   George, Benson M ^a,b,c   McCracken, Melissa N ^a,b   Gupta, Rohit ^a   Tsai, Jonathan M ^a,b,c   Sinha, Rahul ^a,b   Corey, Daniel ^a,b   Ring, Aaron M ^e   Connolly, Andrew J ^a   Weissman, Irving L ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, HUMAN; PDCD1 PROTEIN, MOUSE;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; IMMUNITY; LIGAND; PROTEIN; RODENT; SURVIVAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ENGRAFTMENT; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER STAGING; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD274; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; PHAGOCYTOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019744578     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22396     Document Type: Review

References (34)

1. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
2. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J. Exp. Med. 192, 1027-1034 (2000).
3. Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27, 195-201 (2006).
4. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
5. Zou, W., Wolchok, J. D. & Chen, L PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).
6. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev. Cancer 12, 252-264 (2012).
7. Topalian, S. L et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
8. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
9. Topalian, S. L et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
10. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev. Cancer 4, 71-78 (2004).
11. Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
12. Forty Seven Inc. Phase 1 trial of Hu5F9-G4, a CD47-targeting antibody. https://clinicaltrials.gov/ct2/show/NCT02216409?term= cd47&rank=8 (2014).
13. Celgene. A Phase 1, dose fnding study of CC-90002 in subjects with advanced solid and hematologic cancers. https://clinicaltrials.gov/ct2/show/NCT02367196?term= cd47&rank=7 (2015).
14. Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate infammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303-6308 (2009).
15. Bally, A. P. et al. NF-κ B regulates PD-1 expression in macrophages. J. Immunol. 194, 4545-4554 (2015).
16. Chen, W., Wang, J., Jia, L, Liu, J. & Tian, Y. Attenuation of the programmed cel death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 7, e2115 (2016).
17. Shen, L et al. PD-1/PD-L pathway inhibits M.tb-specifc CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci. Rep. 6, 38362 (2016).
18. Sica, A., Schioppa, T, Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727 (2006).
19. Esashi, E., Sekiguchi, T, Ito, H., Koyasu, S. & Miyajima, A. Cutting edge: a possible role for CD4+ thymic macrophages as professional scavengers of apoptotic thymocytes. J. Immunol. 171, 2773-2777 (2003).
20. Baba, T. et al. CD4+/CD8+ macrophages infltrating at infammatory sites: a population of monocytes/macrophages with a cytotoxic phenotype. Blood 107, 2004-2012 (2006).
21. Zhen, A. et al. CD4 ligation on human blood monocytes triggers macrophage diferentiation and enhances HIV infection. J. Virol. 88, 9934-9946 (2014).
22. Maute, R. L et al. Engineering high-afnity PD-1 variants for optimized mmunotherapy and immuno-PET imaging. Proc. Natl Acad. Sci. USA 112, E6506-E6514 (2015).
23. Klefel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242-1256 (2015).
24. Lin, D. Y. et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011-3016 (2008).
25. Dahan, R. et al. Fcγ Rs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28, 285-295 (2015).
26. Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
27. Benson, D. M. Jr et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma efect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010).
28. Karyampudi, L. et al. PD-1 blunts the function of ovarian tumor-infltrating dendritic cells by inactivating NF-κ B. Cancer Res. 76, 239-250 (2016).
29. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
30. Reichel, J. et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125, 1061-1072 (2015).
31. Saederup, N. et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fuorescent protein knock-in mice. PLoS One 5, e13693 (2010).
32. Maruyama, C. et al. Genotyping the mouse severe combined immunodefciency mutation using the polymerase chain reaction with confronting two-pair primers (PCR-CTPP). Exp. Anim. 51, 391-393 (2002).
33. Takenaka, K. et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 8, 1313-1323 (2007).
34. MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue-and tumor-associated macrophages but does not inhibit infammation. Blood 116, 3955-3963 (2010).